Board of Directors

The Alnylam Board of Directors comprises:

John Clarke, Managing General Partner, Cardinal Partners; founder of Alkermes, Inc. and Cubist Pharmaceuticals, Inc., a founder and chairman of Alnylam Board of Directors

Victor Dzau, M.D., Chancellor for Health Affairs at Duke University, and President and CEO of the Duke University Health System; James B. Duke Professor of Medicine and Director of Molecular and Genomic Vascular Biology at Duke University

Marsha H. Fanucci, former Chief Financial Officer of Millennium Pharmaceuticals. and serves on the Board of Directors at Ironwood Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc

John Maraganore, Ph.D., Chief Executive Officer of Alnylam

Steven M. Paul, M.D, Former President of the Lilly Research Laboratories of Eli Lilly and Company; Former Scientific Director of the National Institute of Mental Health

Paul Schimmel, Ph.D., Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute, National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine member, cofounder of Cubist, Alkermes and Repligen, and a founder and member of the Board of Directors of Alnylam

Phillip Sharp, Ph.D., Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen, Inc. (now Biogen Idec, Inc.) and Alnylam; National Academy of Sciences

Kevin Starr, Partner, Third Rock Ventures; interim CEO of Agios Pharmaceuticals (a portfolio company of Third Rock).; former Chief Operating Officer and Chief Financial Officer of Millennium Pharmaceuticals, Inc.; former Corporate Controller of Biogen, Inc. (now Biogen Idec, Inc.)